CanSino Biologics Inc.康希诺生物

Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to providing high-quality, innovative, and affordable vaccines for global public health security. It possesses five integrated platform technologies upon which the company has established a rich portfolio of a pipeline products preventing more than 10 diseases, including the Aisa's first vaccine for Ebola virus disease Ad5-EBOV, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Convidecia® approved in over 10 countries and granted EUL by the WHO, the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) Menphecia® and the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia® approved by NMPA in China. The world's first inhaled COVID-19 vaccine Convidecia Air® has been approved as a booster dose in China, Morocco, and Indonesia. Additional information can be found online at www.cansinotech.com.